A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

INTRODUCTION: There are few effective treatment options for leptomeningeal metastasis (LM) in non-small-cell lung cancer (NSCLC). This study assessed the feasibility of high-dose gefitinib in patients with LM from NSCLC harboring EGFR mutations or prior systemic response to EGFR-TKI. METHODS: This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackman, David M., Cioffredi, Leigh A., Jacobs, Lorraine, Sharmeen, Farhana, Morse, Linda K., Lucca, Joan, Plotkin, Scott R., Marcoux, Paul J., Rabin, Michael S., Lynch, Thomas J., Johnson, Bruce E., Kesari, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414209/
https://www.ncbi.nlm.nih.gov/pubmed/25784657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414209/
https://www.ncbi.nlm.nih.gov/pubmed/25784657

Ejemplares similares